Baidu
map

JCEM:miR-218-2和其宿主基因SLIT3参与甲状腺癌的发生

2013-06-13 JCEM dxy

在甲状腺癌,内含子miRNAs与其宿主基因功能关系仍不清楚。MiR-218,一种在数种癌症中下调的miRNA,与多种癌症的表型有关,分别从位于SLIT2和SLIT3内含子内的染色体4p15.31(miR-218-1)和5q35.1(miR-218-2)上的两个位点转录。为了探讨miR-218-1和miR-218-2,以及他们的宿主基因SLIT2和SLIT3在甲状腺癌发生中的表达和作用,来自中山大学

在甲状腺癌,内含子miRNAs与其宿主基因功能关系仍不清楚。MiR-218,一种在数种癌症中下调的miRNA,与多种癌症的表型有关,分别从位于SLIT2和SLIT3内含子内的染色体4p15.31(miR-218-1)和5q35.1(miR-218-2)上的两个位点转录。为了探讨miR-218-1和miR-218-2,以及他们的宿主基因SLIT2和SLIT3在甲状腺癌发生中的表达和作用,来自中山大学附属第一医院的李延兵教授及其团队进行了一项研究(Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer),该研究发现miR-218-2和其宿主基因SLIT3参与甲状腺癌细胞侵袭、转移和增殖。这个研究结果突出了内含子miRNAs与其宿主基因在甲状腺癌发生中的功能关系。

该研究中,通过定量RT-PCR评估miR-218-1和miR-218-2,以及他们的宿主基因SLIT2和SLIT3在正常和肿瘤的人类甲状腺组织中的表达。重建甲状腺癌细胞中miR-218-2和SLIT3的表达,并评估他们在细胞侵袭、转移和增殖中的作用。

该研究结果表明,该研究发现在甲状腺癌中伴随着miR-218-2和其宿主基因SLIT3的下调。观察到miR-218-2与SLIT3在甲状腺癌细胞侵袭、转移和增殖中发挥协同抑制作用。此外,miR-218-2在甲状腺癌细胞中的作用至少部分是由于作用于PDGFRA和PLCG1。

该研究暗示miR-218-2和其宿主基因SLIT3参与甲状腺癌细胞侵袭、转移和增殖。这个研究结果突出了内含子miRNAs与其宿主基因在甲状腺癌发生中的功能关系。

Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer.
Abstract
Context:The functional relationships between intronic miRNAs and their host genes in thyroid cancer remain unclear. MiR-218, a miRNA down-regulated in several kinds of cancers and associated with multiple cancer phenotypes, is transcribed from two loci located on chromosomes 4p15.31 (miR-218-1) and 5q35.1 (miR-218-2) within the introns of SLIT2 and SLIT3, respectively.Objective:The aim of our work was to investigate the expression and the roles of miR-218-1 and miR-218-2, as well as their host genes SLIT2 and SLIT3 in thyroid carcinogenesis.Design:The expression of miR-218-1 and miR-218-2, as well as their host genes SLIT2 and SLIT3 in a panel of normal and neoplastic human thyroid tissues was assessed by quantitative RT-PCR. We restored the expression of miR-218-2 and SLIT3 in thyroid cancer cells and evaluated their effects on cell invasion, migration, and proliferation.Results:We found that miR-218-2 and its host gene SLIT3 were down-regulated concomitantly in thyroid cancer. Synergistic inhibitory effects of miR-218-2 with SLIT3 on thyroid cancer cell invasion, migration, and proliferation were observed. Moreover, the effects of miR-218-2 on thyroid cancer cells were due to, at least partially, targeting PDGFRA and PLCG1.Conclusions:These results implicate the involvement of miR-218-2 and its host genes SLIT3 in thyroid cancer cell invasion, migration, and proliferation. Our findings highlight the functional associations of intronic miRNAs and their host genes in thyroid carcinogenesis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930372, encodeId=f94219303e264, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Dec 18 10:16:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703041, encodeId=c9c51e0304116, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Apr 21 01:16:00 CST 2014, time=2014-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777429, encodeId=5e471e77429d2, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 24 15:16:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062808, encodeId=7aaa20628080b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Jun 19 04:16:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722035, encodeId=f9401e22035fe, content=<a href='/topic/show?id=863d4650efe' target=_blank style='color:#2F92EE;'>#宿主基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46507, encryptionId=863d4650efe, topicName=宿主基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db6033130546, createdName=zexyw12, createdTime=Fri Apr 18 12:16:00 CST 2014, time=2014-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404625, encodeId=4dba140462539, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jun 15 04:16:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
    2013-12-18 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930372, encodeId=f94219303e264, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Dec 18 10:16:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703041, encodeId=c9c51e0304116, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Apr 21 01:16:00 CST 2014, time=2014-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777429, encodeId=5e471e77429d2, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 24 15:16:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062808, encodeId=7aaa20628080b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Jun 19 04:16:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722035, encodeId=f9401e22035fe, content=<a href='/topic/show?id=863d4650efe' target=_blank style='color:#2F92EE;'>#宿主基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46507, encryptionId=863d4650efe, topicName=宿主基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db6033130546, createdName=zexyw12, createdTime=Fri Apr 18 12:16:00 CST 2014, time=2014-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404625, encodeId=4dba140462539, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jun 15 04:16:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
    2014-04-21 heli0118
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930372, encodeId=f94219303e264, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Dec 18 10:16:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703041, encodeId=c9c51e0304116, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Apr 21 01:16:00 CST 2014, time=2014-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777429, encodeId=5e471e77429d2, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 24 15:16:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062808, encodeId=7aaa20628080b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Jun 19 04:16:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722035, encodeId=f9401e22035fe, content=<a href='/topic/show?id=863d4650efe' target=_blank style='color:#2F92EE;'>#宿主基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46507, encryptionId=863d4650efe, topicName=宿主基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db6033130546, createdName=zexyw12, createdTime=Fri Apr 18 12:16:00 CST 2014, time=2014-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404625, encodeId=4dba140462539, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jun 15 04:16:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930372, encodeId=f94219303e264, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Dec 18 10:16:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703041, encodeId=c9c51e0304116, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Apr 21 01:16:00 CST 2014, time=2014-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777429, encodeId=5e471e77429d2, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 24 15:16:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062808, encodeId=7aaa20628080b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Jun 19 04:16:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722035, encodeId=f9401e22035fe, content=<a href='/topic/show?id=863d4650efe' target=_blank style='color:#2F92EE;'>#宿主基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46507, encryptionId=863d4650efe, topicName=宿主基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db6033130546, createdName=zexyw12, createdTime=Fri Apr 18 12:16:00 CST 2014, time=2014-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404625, encodeId=4dba140462539, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jun 15 04:16:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
    2013-06-19 achengzhao
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930372, encodeId=f94219303e264, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Dec 18 10:16:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703041, encodeId=c9c51e0304116, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Apr 21 01:16:00 CST 2014, time=2014-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777429, encodeId=5e471e77429d2, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 24 15:16:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062808, encodeId=7aaa20628080b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Jun 19 04:16:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722035, encodeId=f9401e22035fe, content=<a href='/topic/show?id=863d4650efe' target=_blank style='color:#2F92EE;'>#宿主基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46507, encryptionId=863d4650efe, topicName=宿主基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db6033130546, createdName=zexyw12, createdTime=Fri Apr 18 12:16:00 CST 2014, time=2014-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404625, encodeId=4dba140462539, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jun 15 04:16:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1930372, encodeId=f94219303e264, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Dec 18 10:16:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703041, encodeId=c9c51e0304116, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Apr 21 01:16:00 CST 2014, time=2014-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777429, encodeId=5e471e77429d2, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 24 15:16:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062808, encodeId=7aaa20628080b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Jun 19 04:16:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722035, encodeId=f9401e22035fe, content=<a href='/topic/show?id=863d4650efe' target=_blank style='color:#2F92EE;'>#宿主基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46507, encryptionId=863d4650efe, topicName=宿主基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db6033130546, createdName=zexyw12, createdTime=Fri Apr 18 12:16:00 CST 2014, time=2014-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404625, encodeId=4dba140462539, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jun 15 04:16:00 CST 2013, time=2013-06-15, status=1, ipAttribution=)]
    2013-06-15 wincls

相关资讯

FDA批准cabozantinib用于治疗甲状腺髓样癌

       11月29日,美国食品药品监督管理局(FDA)批准了cabozantinib (Cometriq)用于治疗转移性甲状腺髓样癌,尽管该药物在临床试验中并未延长患者的总生存期。很显然,FDA对这种又名XL184的广谱激酶抑制剂在临床试验中显著的PFS(无进展生存期)益处和轻微毒性反应很满意。       &

SCI TRANSL MED :联合药物疗法可延缓甲状腺癌进展

  近日在《科学转化医学》期刊上发表的一项由梅约诊所进行的研究显示,联合使用帕唑帕尼和紫杉醇可降低未分化甲状腺癌(ATC)的发展。梅约诊所肿瘤学家Keith Bible博士介绍称,将这两种药物联合起来使用比分别单独使用的疗效都好。   未分化甲状腺癌是一种罕见但严重的癌症,通常会影响60到80岁之间的人群。这种癌症的侵略性极强,中值生存期仅为5个月,仅有20%的患者在癌症确诊后可存活超过1年。过

JCEM:二甲双胍可抑制分化型甲状腺癌生长

临床试验显示二甲双胍增加癌症患者系统性治疗的疗效。为了验证分化型甲状腺癌(DTC)常规治疗的疗效在糖尿病患者中是否受到二甲双胍治疗的影响,来自美国国防医科大学的Vasyl Vasko教授及其团队进行了一项研究,该研究发现在肿瘤比较小的患者使用二甲双胍治疗,提示通过二甲双胍可抑制肿瘤生长。在糖尿病患者中,缺少二甲双胍治疗是完全缓解(CR)可能性减少和无进展生存期缩短风险增加的独立因素。体外数据提示在

绝经女性每日吃海藻增患甲状腺癌风险

    日本国立癌症研究中心和国立环境研究所4月11日公布调查结果说,绝经女性如果每天食用海藻,其患甲状腺癌的风险会显著升高。   调查显示,与每周吃海藻不到两次的人相比,几乎每天食用海藻的绝经女性患甲状腺癌的风险是前者的2.43倍。研究小组成员、国立环境研究所的科研人员说,这可能与海藻中的碘有关。   海藻中含量丰富的碘是维持健康所必需的矿物质,但是专家认为过量

Cancer Causes Control:吸烟饮酒或与甲状腺癌风险降低相关

  《癌症病因与控制》(Cancer Causes Control)杂志近期发表的一项汇总分析(pooled analysis)结果提示,吸烟和饮酒均与甲状腺乳头状癌风险降低相关,并且可能与甲状腺滤泡癌风险降低相关。   在这项关于5项前瞻性研究的384433例男性和361664例女性的汇总分析中,研究者评估了吸烟、饮酒和甲状腺癌风险的相关性。   在吸烟和饮酒互

2012中国甲状腺结节和分化型甲状腺癌指南

前 言 甲状腺结节和甲状腺癌是内分泌系统的多发病和常见病。触诊获得的甲状腺结节患病率为3-7%,高分辨率B超检查获得的甲状腺结节的患病率为20-76%。甲状腺结节中的甲状腺癌的患病率为5-15%。近年来我国甲状腺癌的发病率呈现增高的趋势,非必要的甲状腺结节的手术率也显著升高。甲状腺癌的术式、放射性碘治疗、TSH抑制疗法和甲状腺癌复发的监测等方面都缺乏共识和规范。 甲状腺结节和甲状腺癌的诊断和治

Baidu
map
Baidu
map
Baidu
map